Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated:  3/28/2018
Aspirus Regional Cancer Center
mi
from
Wausau, WI
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated: 3/28/2018
Aspirus Regional Cancer Center
mi
from
Wausau, WI
Click here to add this to my saved trials
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated:  3/28/2018
WellSpan Health-York Hospital
mi
from
York, PA
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated: 3/28/2018
WellSpan Health-York Hospital
mi
from
York, PA
Click here to add this to my saved trials
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated:  3/28/2018
Cross Cancer Institute
mi
from
Edmonton,
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated: 3/28/2018
Cross Cancer Institute
mi
from
Edmonton,
Click here to add this to my saved trials
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated:  3/28/2018
Sands Cancer Center
mi
from
Canandaigua, NY
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated: 3/28/2018
Sands Cancer Center
mi
from
Canandaigua, NY
Click here to add this to my saved trials
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated:  3/28/2018
UHHS Chagrin Highlands Medical Center
mi
from
Orange Village, OH
Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Status: Enrolling
Updated: 3/28/2018
UHHS Chagrin Highlands Medical Center
mi
from
Orange Village, OH
Click here to add this to my saved trials
Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer
A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer
Status: Enrolling
Updated:  3/28/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer
A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer
Status: Enrolling
Updated: 3/28/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated:  3/28/2018
UPMC CancerCetner
mi
from
Pittsburgh, PA
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer
Status: Enrolling
Updated: 3/28/2018
UPMC CancerCetner
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Northwestern Medical Faculty Foundation, Div of Hematology/Oncology
mi
from
Chicago, IL
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Northwestern Medical Faculty Foundation, Div of Hematology/Oncology
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated:  3/28/2018
Cliniques Universitaires Saint-Luc
mi
from
Brussels,
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
A Prospective Randomized Clinical Trial on 90Yttrium Trans-arterial Radio-Embolization (TheraSphere®) vs. Standard of Care (Sorafenib) for the Treatment of Advanced Hepatocellular Carcinoma (HCC) With Portal Vein Thrombosis (PVT)
Status: Enrolling
Updated: 3/28/2018
Cliniques Universitaires Saint-Luc
mi
from
Brussels,
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
Massachusetts General Hospital
mi
from
Boston, MA
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated:  3/28/2018
Fundacion Jimenez Diaz
mi
from
Madrid,
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
A Phase 1 Study of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
Status: Enrolling
Updated: 3/28/2018
Fundacion Jimenez Diaz
mi
from
Madrid,
Click here to add this to my saved trials
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Status: Enrolling
Updated:  3/28/2018
Indiana University Hospital
mi
from
Indianapolis, IN
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Status: Enrolling
Updated: 3/28/2018
Indiana University Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Status: Enrolling
Updated:  3/28/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Phase I Study of the Hypomethylating Drug SGI-110 Plus Cisplatin in Relapsed Refractory Germ Cell Tumors
Status: Enrolling
Updated: 3/28/2018
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Status: Enrolling
Updated:  3/28/2018
Indiana University Health Hospital
mi
from
Indianapolis, IN
Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Status: Enrolling
Updated: 3/28/2018
Indiana University Health Hospital
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Status: Enrolling
Updated:  3/28/2018
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Status: Enrolling
Updated: 3/28/2018
Indiana University Health Melvin And Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Status: Enrolling
Updated:  3/28/2018
Mayo Clinic Department of Medical Oncology
mi
from
Rochester, MN
Study of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
A Study of the Natural History of Cisplatin-Induced Peripheral Neuropathy in Patients With Germ Cell Tumor
Status: Enrolling
Updated: 3/28/2018
Mayo Clinic Department of Medical Oncology
mi
from
Rochester, MN
Click here to add this to my saved trials
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors
Status: Enrolling
Updated:  3/28/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
A Phase-I Study Of Cyclical Oral Administration Of Temozolomide In Combination With PEG12000-Interferon Alfa-2B In Patients With Refractory And/Or Advanced Solid Tumors
Status: Enrolling
Updated: 3/28/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
Status: Enrolling
Updated:  3/28/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
Status: Enrolling
Updated: 3/28/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
Status: Enrolling
Updated:  3/28/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
Status: Enrolling
Updated: 3/28/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
Status: Enrolling
Updated:  3/28/2018
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia
Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study
Status: Enrolling
Updated: 3/28/2018
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Capecitabine For Nasopharyngeal Cancer
A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
Status: Enrolling
Updated:  3/28/2018
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Capecitabine For Nasopharyngeal Cancer
A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
Status: Enrolling
Updated: 3/28/2018
University of Chicago Cancer Research Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Capecitabine For Nasopharyngeal Cancer
A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
Status: Enrolling
Updated:  3/28/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Capecitabine For Nasopharyngeal Cancer
A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
Status: Enrolling
Updated: 3/28/2018
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Capecitabine For Nasopharyngeal Cancer
A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
Status: Enrolling
Updated:  3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Capecitabine For Nasopharyngeal Cancer
A Phase II Study Of Capecitabine In Previously Treated, Recurrent And/Or Metastatic Nasopharyngeal Carcinoma
Status: Enrolling
Updated: 3/28/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated:  3/29/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer
A Phase 1 Study With Dose Expansion of Dinaciclib (SCH 727965) in Combination With Epirubicin in Patients With Metastatic Triple Negative Breast Cancer
Status: Enrolling
Updated: 3/29/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated:  3/29/2018
Montefiore Medical Center
mi
from
New York, NY
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated: 3/29/2018
Montefiore Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated:  3/29/2018
Rhode Island Hospital
mi
from
Providence, RI
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated: 3/29/2018
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated:  3/29/2018
Miriam Hospital
mi
from
Providence, RI
A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer
BrUOG 276: A Phase I/II Evaluation of ADXS11-001, Mitomycin,5-fluorouracil (5-FU) and IMRT for Anal Cancer
Status: Enrolling
Updated: 3/29/2018
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated:  3/29/2018
Cedars Sinai
mi
from
West Hollywood, CA
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated: 3/29/2018
Cedars Sinai
mi
from
West Hollywood, CA
Click here to add this to my saved trials
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated:  3/29/2018
University of Iowa
mi
from
Iowa City, IA
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated: 3/29/2018
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated:  3/29/2018
Memorial Sloan-Kettering
mi
from
New York, NY
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated: 3/29/2018
Memorial Sloan-Kettering
mi
from
New York, NY
Click here to add this to my saved trials
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated:  3/29/2018
University of Oklahoma
mi
from
Norman, OK
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated: 3/29/2018
University of Oklahoma
mi
from
Norman, OK
Click here to add this to my saved trials
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated:  3/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer
Status: Enrolling
Updated: 3/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Effects of Meditation on Cognitive Function and Quality of Life
Effects of Meditation on Cognitive Function and Quality of Life
Status: Enrolling
Updated:  3/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Effects of Meditation on Cognitive Function and Quality of Life
Effects of Meditation on Cognitive Function and Quality of Life
Status: Enrolling
Updated: 3/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Effects of Meditation on Cognitive Function and Quality of Life
Effects of Meditation on Cognitive Function and Quality of Life
Status: Enrolling
Updated:  3/29/2018
Hospital Israelita Albert Einstein (HIAE)
mi
from
Sao Paulo,
Effects of Meditation on Cognitive Function and Quality of Life
Effects of Meditation on Cognitive Function and Quality of Life
Status: Enrolling
Updated: 3/29/2018
Hospital Israelita Albert Einstein (HIAE)
mi
from
Sao Paulo,
Click here to add this to my saved trials
Sublingual Fentanyl for the Management of Breakthrough Pain
A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients With Advanced Cancer
Status: Enrolling
Updated:  3/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Sublingual Fentanyl for the Management of Breakthrough Pain
A Preliminary Study of Sublingual Fentanyl for the Management of Breakthrough Pain Analgesia in Patients With Advanced Cancer
Status: Enrolling
Updated: 3/29/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
Laura and Isaac Permutter Cancer Center @ NYU Langone
mi
from
New York, NY
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
Laura and Isaac Permutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
The Ohio State University James Cancer Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated:  3/29/2018
Swedish Cancer Institute
mi
from
Seattle, WA
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
Status: Enrolling
Updated: 3/29/2018
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
University of Southern CA
mi
from
Los Angeles, CA
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
University of Southern CA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Florida Hospital
mi
from
Florida City, FL
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Florida Hospital
mi
from
Florida City, FL
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Tampa General Hospital
mi
from
Tampa, FL
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
University of Chicago
mi
from
Chicago, IL
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Ochsner Clinic Foundation
mi
from
Jefferson, LA
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Ochsner Clinic Foundation
mi
from
Jefferson, LA
Click here to add this to my saved trials
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated:  3/29/2018
Washington University
mi
from
Saint Louis, MO
Efficacy and Safety of LifeSeal™ Kit for Colorectal Staple Line Sealing
Efficacy and Safety of LifeSeal™ Kit for Staple Line Sealing in Colorectal and Coloanal Anastomoses: A Prospective Randomized Study
Status: Enrolling
Updated: 3/29/2018
Washington University
mi
from
Saint Louis, MO
Click here to add this to my saved trials